Skip to main content Skip to footer

Pre-prints and published manuscripts from the AGILE COVID-19 platform

Publications

An open label, adaptive, phase 1 trial of high-dose oral nitazoxanide in healthy volunteers: an antiviral candidate for SARS-CoV-2

Practical recommendations for implementing a Bayesian adaptive phase I design during a pandemic

AGILE-ACCORD: A Randomized, Multicentre, Seamless, Adaptive Phase I/II Platform Study to Determine the Optimal Dose, Safety and Efficacy of Multiple Candidate Agents for the Treatment of COVID-19: A structured summary of a study protocol for a randomised platform trial

AGILE: a seamless phase I/IIa platform for the rapid evaluation of candidates for COVID-19 treatment: an update to the structured summary of a study protocol for a randomised platform trial letter

Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study.

Shutting the gate before the horse has bolted: is it time for a conversation about SARS-CoV-2 and antiviral drug resistance?

Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5′-triphosphate exposure to support posology for SARS-CoV-2

Scalable nanoprecipitation of niclosamide and in vivo demonstration of long-acting delivery after intramuscular injection

COVID-19 chemotherapeutics without putting the cart before the horse

Toward Consensus on Correct Interpretation of Protein Binding in Plasma and Other Biological Matrices for COVID-19 Therapeutic Development

Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis

Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics

The development and validation of a novel LC-MS/MS method for the simultaneous quantification of Molnupiravir and its metabolite ß-d-N4-hydroxycytidine in human plasma and saliva

Pre-prints

Pharmacokinetics of ß-d-N4-hydroxycytidine, the active metabolite of prodrug molnupiravir, in non-plasma compartments of patients with SARS-CoV-2 infection

Evaluation of intranasal nafamostat or camostat for SARS-CoV-2 chemoprophylaxis in Syrian golden hamsters

Quantitation of tizoxanide in multiple matrices to support cell culture, animal and human research

Development of a highly sensitive bioanalytical assay for the quantification of favipiravir

Optimisation and validation of a sensitive bioanalytical method for Niclosamide

Conference Proceedings

Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a phase 1, open-label, dose-escalating, randomised controlled studyInternational Workshop on Clinical Pharmacology of HIV, Hepatitis and Other Antiviral Drugs 2021

MEETING REPORT: Meeting Report Day 1 | S. Khoo | by M. Mascolini | AME academicmedicaleducation.com)

An open label, adaptive, phase 1 trial of high-dose oral nitazoxanide in healthy volunteers: an antiviral candidate for treatment of COVID-19International Workshop on Clinical Pharmacology of HIV, Hepatitis and Other Antiviral Drugs 2021

MEETING REPORT: Meeting Report Day 1 | L. Walker | by M. Mascolini | AME (academicmedicaleducation.com)

Abstract: SALIVA, NASAL & TEAR PK OF EIDD-1931 IN PATIENTS WITH COVID-19 RECEIVING MOLNUPIRAVIR (croiconference.org)